We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

131 hedge funds and large institutions have $423M invested in Intra-Cellular Therapies Inc. in 2016 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 45 increasing their positions, 38 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 38

11% more call options, than puts

Call options by funds: $16.3M | Put options by funds: $14.8M

6% less funds holding

Funds holding: 139 → 131 (-8)

26% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 31

64% less capital invested

Capital invested by funds: $1.19B → $423M (-$763M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
131
Holders Change
-8
Holders Change %
-5.76%
% of All Funds
3.5%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.03%
New
23
Increased
45
Reduced
38
Closed
31
Calls
$16.3M
Puts
$14.8M
Net Calls
+$1.55M
Net Calls Change
-$6.55M

Top Buyers

Rank Fund Capital Flow
1
HIM
Hillhouse Investment Management
Cayman Islands
+$40.4M
2
BB
BB Biotech
Switzerland
+$26.3M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$22.4M
4
SIM
Spark Investment Management
New York
+$8.08M
5
Goldman Sachs
Goldman Sachs
New York
+$7.04M

Top Sellers

Rank Fund Capital Flow
1
BA
BlackRock Advisors
Delaware
-$39.4M
2
O
OrbiMed
New York
-$35.8M
3
RG
Redmile Group
California
-$25.7M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$20.2M
5
BG
BlackRock Group
United Kingdom
-$17.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
RSCM
26
Rock Springs Capital Management
Maryland
$2.9M – – –
Deutsche Bank
27
Deutsche Bank
Germany
$2.65M +$6.63M +163,916 +1,576%
CCP
28
Clough Capital Partners
Massachusetts
$2.62M -$2.18M -53,800 -24%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$2.41M -$773K -19,118 -11%
Point72 Asset Management
30
Point72 Asset Management
Connecticut
$2.34M -$647K -16,000 -9%
BIM
31
BlackRock Investment Management
Delaware
$2.2M -$2.19M -54,121 -27%
RPAM
32
Rhenman & Partners Asset Management
Sweden
$2.06M +$809K +20,000 +17%
Charles Schwab
33
Charles Schwab
California
$1.89M +$525K +12,984 +12%
SEI Investments
34
SEI Investments
Pennsylvania
$1.73M +$78.3K +1,936 +2%
CS
35
Candriam SCA
Luxembourg
$1.68M -$4.81M -119,000 -52%
PAMU
36
Pictet Asset Management (UK)
United Kingdom
$1.64M +$4.35M +107,648 New
FCM
37
Frontier Capital Management
Massachusetts
$1.62M +$994K +24,582 +30%
Simplex Trading
38
Simplex Trading
Illinois
$1.58M +$4.18M +103,463 New
WRF
39
Waddell & Reed Financial
Kansas
$1.44M – – –
TAM
40
Tocqueville Asset Management
New York
$1.4M +$226K +5,600 +6%
EIM
41
Essex Investment Management
Massachusetts
$1.29M +$2.75M +67,964 +411%
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$1.11M +$28.3K +700 +1%
AWCI
43
Alpine Woods Capital Investors
New York
$1.07M +$704K +17,400 +33%
TA
44
Teachers Advisors
New York
$1.07M -$163K -4,025 -5%
OAM
45
Oxford Asset Management
United Kingdom
$1.03M +$2.74M +67,654 New
CWG
46
C WorldWide Group
Denmark
$1.03M -$4.77M -118,000 -64%
State of New Jersey Common Pension Fund D
47
State of New Jersey Common Pension Fund D
New Jersey
$953K – – –
Citadel Advisors
48
Citadel Advisors
Florida
$873K +$1.39M +34,426 +151%
BG
49
BlackRock Group
United Kingdom
$854K -$17.4M -429,541 -88%
AllianceBernstein
50
AllianceBernstein
Tennessee
$844K – – –
1
2
3 4 5

ITCI Hedge Fund Activity: Q3 2016 in Review

131 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2016, worth a combined $423M — down 64% from $1.19B a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of ITCI and 23 opened new positions — a net loss of 8 holders — while 38 trimmed existing stakes and 45 added.

The largest buyer was Hillhouse Investment Management, opening a new position worth an estimated $40.4M. The largest seller was BlackRock Advisors, cutting an estimated $39.4M.

  • 131 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2016, down from 139 in Q2 2016.
  • Funds reported $423M of Intra-Cellular Therapies Inc. stock for Q3 2016, down 64% quarter-over-quarter.
  • 23 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2016 and 31 closed out, a net change of -8 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q3 2016 was Hillhouse Investment Management, an estimated $40.4M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q3 2016 was BlackRock Advisors, an estimated $39.4M sold.

Based on aggregated 13F filings for Q3 2016.